Review decision – December 2018
Decision to move the existing guidance to the static list
We would like to update you on the decision made regarding the review of the existing guidance on TA373; Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis.
There has been no change to the marketing authorisations relating to juvenile idiopathic arthritis for the 4 treatments. There is no new evidence that is likely to lead to a change in the current recommendations.
NICE’s Guidance Executive has decided to proceed with this proposal without consultation.
Consequently, TA373 will move to the ‘static list’ of technology appraisals.
This page was last updated: 31 December 2018